Fight for Sight aims to stop sight loss by funding pioneering research. Rod McNeil takes a look at the Primer Fellowship Awards programme, which provides funding for up to £60,000 for individuals to undertake vision-related research for one year. Among...
Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...
The authors share their investigation at Manchester Royal Eye Hospital into the association between diabetes and AAU. The global prevalence of diabetes mellitus (DM) is rapidly rising from an estimated 9.3% in 2019 to 10.2% by 2030 [1]. The link...
See also - See sweet to C-suite: Imran Rahman In this three-part conversation series, Co-editor David Lockington speaks with highly influential individuals about their journey to the top, with advice for the next generation of leaders. Part One: David speaks...
Dry eye disease (DED) and ocular surface disease (OSD) are increasingly recognised as central factors in contemporary intraocular surgery. As cataract, glaucoma and vitreoretinal procedures advance toward greater refractive precision, patient expectations have risen and tolerance for postoperative visual fluctuation...
Implementation of biosimilars in NHS retinal services A NHS England (NHSE) perspective Luke Nicholson (Moorfields Eye Hospital) explained that the NHSE perspective overall is structured on best value medicine for the patient and system, accounting for a finite budget and...
Back in 1993, the late and great Barry Cullen FRCS (Cavan born, Dublin trained), the first editor of Eye News, asked me to write an article about the current treatment of chronic open angle glaucoma (COAG). At the time I...
3 October 2024
| Elliott Taylor, Covadonga Bascaran, Islay Mactaggart, Farhana Rehman-Furs, Andrew Bastawrous, Marcia Zondervan, Matthew J Burton
|
EYE - Vitreo-Retinal
Technological innovation is providing new solutions to transform global eye health [1–5]. In particular, research towards the development of artificial intelligence (AI) tools in ophthalmology has gained pace in recent years. However, there has been little research relating to its...
A community optometrist examines what the high street needs before artificial intelligence (AI)-enabled systemic risk assessment moves from laboratory to consulting room. Few areas of AI have advanced as rapidly as oculomics. Within little more than a decade, retinal imaging...
Glaucoma is a leading cause of irreversible vision loss worldwide, affecting millions around the globe [1]. Despite major advances in glaucoma treatment, complications of surgery and long-term disease management remain challenging due to poor adherence to topical medications, fluctuating intraocular...
Part 2: Clinical presentation and treatment (see part 1 here) Introduction IgG4-related disease (IgG4-RD) is understood to have a vast clinicopathological spectrum; nearly every organ has had reported involvement. Similarly, IgG4-related ophthalmic disease (IgG4-ROD) is known to affect nearly every...
4 October 2023
| Marcia Zondervan, Hannah Faal, Covadonga Bascaran
|
EYE - General
The VISION 2020 LINKS & Networks Programme has been writing regular articles in Eye News about its capacity-strengthening activities in low- and middle-income countries (LMICs) for more than a decade. This, the first International Issue, is a landmark for Eye...